SOURCE: Basilea Pharmaceutica AG

September 11, 2007 01:31 ET

Basilea Announces the Submissions of Marketing Authorization Applications in the EU for Alitretinoin, an Investigational Drug for the Treatment of Severe Refractory Chronic Hand Eczema

BASEL, SWITZERLAND--(Marketwire - September 11, 2007) -



Basel, Switzerland, September 11, 2007 - Basilea Pharmaceutica Ltd. (SWX: BSLN) announced today the submissions of Marketing Authorization Applications (MAA) under the decentralized procedure to various EU member states for alitretinoin. These submissions support the proposed use of oral alitretinoin in severe refractory chronic hand eczema.

The Marketing Authorization Applications (MAA) seek approval for oral alitretinoin in the treatment of severe refractory chronic hand eczema (CHE) and are based on a clinical program comprising almost 2000 patients.

Dr. Anthony Man, CEO of Basilea said, "We intend to build a fully integrated hospital and specialty care business focused on serving high medical needs. The submission of our second European product marketing authorization application this year is another significant step towards our goal."

About Chronic Hand Eczema (CHE)

Hand eczema is a common skin disease and is often chronic and relapsing. It is estimated to affect up to 10% of the general population. The more severe, chronic form of the condition is thought to affect up to 7% of these patients, many of whom do not respond, or no longer respond to topical corticosteroids. Basilea estimates there are at least five hundred thousand patients in Europe with refractory severe CHE.

About Basilea

Basilea Pharmaceutica Ltd. is an independent biopharmaceutical company headquartered in Basel, Switzerland, listed on the SWX Swiss Exchange (SWX: BSLN). Basilea's fully integrated research and development operations are currently focused on new antibacterial and antifungal agents to fight drug resistance and on the development of dermatology drugs. Basilea's products are targeted to satisfy high medical and patient needs in the hospital and specialty care setting.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Basilea Pharmaceutica Ltd. and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.


For further information, please contact:

+----------------------------------------------------------+
| General Information     | Investor Relations             |
|-------------------------+--------------------------------|
| information@basilea.com | Dr. Barbara Zink               |
|                         | investor_relations@basilea.com |
+----------------------------------------------------------+


This press release can be downloaded from www.basilea.com

The press release can also be downloaded from the following link:

http://hugin.info/134390/R/1152676/221507.pdf



Copyright © Hugin ASA 2007. All rights reserved.

Contact Information